Updated:
Rani Therapeutics
Rani Therapeutics is a clinical-stage biotech founded by Mir Imran developing the RaniPill, a robotic capsule that delivers injectable drugs orally.
Rani Therapeutics
Rani Therapeutics was founded in 2012 by serial entrepreneur Mir Imran, who chairs the company, with Talat Imran serving as CEO. The firm originated inside InCube Labs, Imran's life-sciences incubator, and was spun out to commercialize a platform technology designed to administer biologics orally — a structural breakthrough in pharmaceutical delivery. The underlying wealth and backing trace to venture investors rather than a single-family fortune; the company has been funded through institutional venture rounds and public markets rather than operating as a family office. The company's strategy centers on developing the RaniPill platform for high-value biologics currently delivered only by injection. The pipeline targets indications including psoriatic arthritis, osteoporosis, and hemophilia. Rani has completed Phase 1 clinical trials demonstrating the capsule can deliver an adalimumab biosimilar with bioavailability comparable to subcutaneous injection. In addition to its internal programs, the company has a partnership with Celltrion to develop an oral version of Humira, and is working with AstraZeneca on an oral GLP-1 peptide. The firm operates from San Jose, California, and conducts clinical work across multiple US sites. Rani went public in August 2021 through a merger with a B. Riley Principal Merger Corp., a special-purpose acquisition company that valued the combined entity at roughly $900 million. The transaction added capital to fund Phase 2 and Phase 3 trials. As of early 2024 the company had no approved products or recurring revenue, making it a pre-revenue biotech platform. The team remains compact and research-focused. In July 2024, Rani completed a Phase 1 study for RT-111, an oral ustekinumab biosimilar being developed with Celltrion (per Reuters, July 2024). The company's structural differentiator is its vertical integration of engineering and biology under one roof — it designs, manufactures, and tests the robotic capsules internally, combining medical-device precision with biologic drug development. This hybrid hardware-biotech model is rare among oral-biologic startups, which typically outsource device development. Governance rests with Mir Imran, who holds the chairman role, while Talat Imran runs day-to-day operations, a succession structure that keeps the founding vision intact while professionalizing execution.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Jose
Corporate office
San Jose, CA, United States
Principals
Talat Imran
Chief Executive Officer
Mir Imran
Executive Chairman
Sector focus
Frequently asked questions
Who makes investment decisions at Rani Therapeutics?
As a public operating company, capital-allocation decisions rest with CEO Talat Imran and the board of directors, chaired by founder Mir Imran. The firm is not a fund manager; it deploys capital into R&D and clinical trials for its own drug pipeline. Strategic financing decisions are subject to standard public-company governance.
How does the RaniPill technology actually work?
The RaniPill is an ingestible capsule that protects a biologic payload until it reaches the small intestine. Once there, an enteric coating dissolves, and a chemical reaction inflates a tiny balloon that presses a dissolvable microneedle array containing the drug into the intestinal wall. Because the intestine lacks sharp-pain receptors, the injection is painless. The device components are then excreted normally.
Is Rani Therapeutics a family office or a biotech company?
Rani Therapeutics is a clinical-stage biotechnology company, not a family office. It was founded inside InCube Labs, Mir Imran's life-sciences incubator, and has been funded by venture capital and public equity markets. Any financial-institution record labeling it as a family office is a classification error.
Which pharmaceutical partners is Rani working with, and on what terms?
Rani has a publicly disclosed partnership with Celltrion to develop an oral ustekinumab biosimilar (RT-111), which completed Phase 1 trials in 2024. It is also collaborating with AstraZeneca on an oral GLP-1 peptide for metabolic disease. Specific milestone payments and royalty terms have not been fully disclosed.
Does Rani Therapeutics generate revenue?
No. As of early 2024, Rani is a pre-revenue biotech with no approved products. The company funds operations through existing cash reserves, partnership milestone payments, and occasional public-market capital raises.
What is the relationship between Mir Imran and Talat Imran?
Mir Imran and Talat Imran are brothers. Mir founded the company and serves as Executive Chairman, while Talat has served as CEO since 2012. The firm's governance reflects a common Silicon Valley pattern where the technical founder remains chairman while a sibling handles operational leadership.
What competitive advantage does Rani have over other oral-biologic companies?
Rani's core advantage is that it manufactures its own robotic capsules, combining precision-engineering and biologic formulation in a single vertically integrated facility. Most competitors outsource device manufacturing. The company has also generated human proof-of-concept data for multiple drug candidates, derisking the platform relative to preclinical-stage peers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: